Yamo Pharmaceuticals is developing L1-79, a novel therapy that targets the core symptoms of autism and has been well-tolerated by clinical trial patients to-date. The mechanism of action for L1-79 addresses both the central nervous system and metabolic symptoms of autism.
Company Details
- Employees
- 8
- Founded
- 2015
- Address
- 750 Lexington Ave,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.yamopharma.com/
- HQ
- New York, NY
Yamo Pharmaceuticals Questions
Yamo Pharmaceuticals's website is https://www.yamopharma.com/
Yamo Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/yamo-pharmaceuticals
Yamo Pharmaceuticals has
8 employees.
View email and phone details for 8
employees at Yamo Pharmaceuticals.
Yamo Pharmaceuticals's industry is
Biotechnology Research
Yamo Pharmaceuticals's top competitors are
Ingenus Pharmaceuticals,
Scioto Biosciences, Inc,
Stalicla,
Curemark, Llc,
Ars Pharmaceuticals, Inc.,
Earlitec Diagnostics, Inc.,
Axial,
Atossa Therapeutics, Inc.,
Mix Talent,
Vertex Pharmaceuticals.
Yamo Pharmaceuticals's categories are Biotechnology Research
Yamo Pharmaceuticals's founding year is 2015
